The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: Oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC).
 
Eric Assenat
Honoraria - Bayer; Novartis; Sirtex Medical
Consulting or Advisory Role - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Ipsen
 
Rosine Guimbaud
Travel, Accommodations, Expenses - Merck Serono; Roche
 
Julien Fraisse
No Relationships to Disclose
 
Emmanuelle Samalin
Consulting or Advisory Role - Amgen; Roche; Sanofi
Research Funding - Merck (Inst); Nordic Bioscience (Inst)
Travel, Accommodations, Expenses - BMS Brazil; Ipsen; Roche
 
Fabienne Portales
Honoraria - Sanofi
Travel, Accommodations, Expenses - Roche
 
Thibault Mazard
Honoraria - Bayer; Sanofi
Research Funding - Amgen (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Lobna Rifai
No Relationships to Disclose
 
Jean-Pierre Delord
No Relationships to Disclose
 
Marc Ychou
Consulting or Advisory Role - Amgen; Bayer; Roche; SERVIER